Synergy Pharmaceuticals (FRA:S90) Change In Receivables : €-3.53 Mil (TTM As of Sep. 2018)

View and export this data going back to 2012. Start your Free Trial

What is Synergy Pharmaceuticals Change In Receivables?

Synergy Pharmaceuticals's change in receivables for the quarter that ended in Sep. 2018 was €-0.61 Mil. It means Synergy Pharmaceuticals's Accounts Receivable increased by €0.61 Mil from Jun. 2018 to Sep. 2018 .

Synergy Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2017 was €-5.49 Mil. It means Synergy Pharmaceuticals's Accounts Receivable increased by €5.49 Mil from Dec. 2016 to Dec. 2017 .

Synergy Pharmaceuticals's Accounts Receivable for the quarter that ended in Sep. 2018 was €7.90 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Synergy Pharmaceuticals's Days Sales Outstanding for the three months ended in Sep. 2018 was 75.77.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Synergy Pharmaceuticals's liquidation value for the three months ended in Sep. 2018 was €-99.37 Mil.

Synergy Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Synergy Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synergy Pharmaceuticals Change In Receivables Chart

Synergy Pharmaceuticals Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Change In Receivables

Get a 7-Day Free Trial

-5.49

Synergy Pharmaceuticals Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Change In Receivables	Get a 7-Day Free Trial															-2.73	-1.23	-0.75	-0.94	-0.61

Synergy Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.53 Mil.

Synergy Pharmaceuticals (FRA:S90) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Synergy Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Sep. 2018 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	7.903	/	9.517	*	91
=	75.77

2. In Ben Graham's calculation of liquidation value, Synergy Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Synergy Pharmaceuticals's liquidation value for the quarter that ended in Sep. 2018 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	39.119	-	153.646	+	0.75 * 7.903	+	0.5 * 18.451
=	-99.37

Synergy Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Synergy Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Synergy Pharmaceuticals (FRA:S90) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Synergy Pharmaceuticals Inc (FRA:S90) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

420 Lexington Avenue, Suite 2012, New York, NY, USA, 10170

Website

http://www.synergypharma.com

Synergy Pharmaceuticals Inc functions in the healthcare sector based in the United States. It focusses on developing therapies to combat gastrointestinal diseases. The company's basic ingredient is the uroguanylin analog, which it employs in its products candidates such as plecanatide and dolcanatide. Plecanatide is a once-daily tablet, which addresses chronic idiopathic constipation and the irritable bowel syndrome. Dolcanatide is meant to cure inflammatory bowel disease by aiding the process of digestive breakdown.

Synergy Pharmaceuticals (FRA:S90) Headlines

No Headlines